MYTELASE Drug Patent Profile
✉ Email this page to a colleague
When do Mytelase patents expire, and what generic alternatives are available?
Mytelase is a drug marketed by Sanofi Aventis Us and is included in one NDA.
The generic ingredient in MYTELASE is ambenonium chloride. Additional details are available on the ambenonium chloride profile page.
AI Research Assistant
Questions you can ask:
- What is the 5 year forecast for MYTELASE?
- What are the global sales for MYTELASE?
- What is Average Wholesale Price for MYTELASE?
Summary for MYTELASE
| US Patents: | 0 |
| Applicants: | 1 |
| NDAs: | 1 |
| Raw Ingredient (Bulk) Api Vendors: | 44 |
| Patent Applications: | 318 |
| DailyMed Link: | MYTELASE at DailyMed |
US Patents and Regulatory Information for MYTELASE
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sanofi Aventis Us | MYTELASE | ambenonium chloride | TABLET;ORAL | 010155-002 | Approved Prior to Jan 1, 1982 | DISCN | No | No | ⤷ Sign Up | ⤷ Sign Up | ⤷ Sign Up | ||||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
